A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer.
Lung Cancer
; 63(1): 88-93, 2009 Jan.
Article
en En
| MEDLINE
| ID: mdl-18538889
ABSTRACT
PURPOSE:
To investigate the efficacy and tolerability of high-dose pemetrexed as second-line chemotherapy in small cell lung cancer (SCLC). PATIENTS ANDMETHODS:
Patients with verified SCLC who had received one prior chemotherapy regimen, aged 18-75 years, WHO Performance Status 0-2, no clinical signs of brain metastases and measurable disease were eligible. Patients received pemetrexed 900 mg/m(2) IV every 3 weeks. Four courses were planned for all patients. Patients with relapse later than 3 months since last course of first-line chemotherapy were defined as "sensitive", those with relapse within 3 months as "refractory". Toxicity was graded using the CTCAE v3.0.RESULTS:
36 patients were accrued, 34 received study treatment. Median age was 61 (range 43-74), 18 (53%) males and 16 (47%) females. Mean number of courses administered was 2.5. One patient (3%) had partial response, three (9%) had stable disease and 29 (85%) progressed. One patient (3%) was not evaluable for response. Median TTP (n=33) was 7.7 weeks ("sensitive" 8.4 weeks, "refractory" 5.1 weeks). Median OS (n=34) was 17.6 weeks ("sensitive" 22.6 weeks, "refractory" 15.3 weeks). Of grade 3-4 haematological toxicity, anemia was observed in 2 (6%) patients, leukopenia in 6 (18%), granulocytopenia in 9 (27%) and thrombocytopenia in 3 (9%). Febrile neutropenia occurred in 6 (18%) patients. There were no treatment related deaths.CONCLUSION:
High-dose pemetrexed monotherapy to patients with recurrent SCLC yielded moderate toxicity, but limited treatment efficacy.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Carcinoma Pulmonar de Células Pequeñas
/
Glutamatos
/
Guanina
/
Neoplasias Pulmonares
/
Antimetabolitos Antineoplásicos
Tipo de estudio:
Clinical_trials
/
Observational_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Lung Cancer
Asunto de la revista:
NEOPLASIAS
Año:
2009
Tipo del documento:
Article
País de afiliación:
Noruega